Stocktoria
Scienture Holdings, Inc. SCNX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-02-18
Scienture Holdings, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 76.8% | 4.4% | 3.6% | 53.8% | 48.0% |
| Operating margin | -9867.9% | -10758.7% | -322.4% | -28.4% | -53.5% |
| Net margin | -9618.0% | 6634.7% | -1308.3% | -33.9% | -53.8% |
| FCF margin | — | -10448.6% | — | — | -26.2% |
| Return on assets | -49.3% | 8.6% | -142.4% | -93.6% | -92.2% |
| Return on equity | -59.2% | 11.5% | -3290.0% | -455.0% | -141.0% |
| Debt / equity | — | 0.04× | — | — | — |
| Current ratio | 2.89 | 0.80 | 0.24 | 0.98 | 4.72 |
| Revenue growth | 215.9% | -90.0% | -86.7% | 3.6% | -42.2% |
Source: SEC EDGAR filings · CIK 0001382574 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.